Search

Search Constraints

You searched for: Author/Creator Rae, James M.

Search Results

1. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Issue 10 (1st April 2023)

2. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. (8th April 2016)

3. Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy. Issue 5 (4th February 2020)

4. Genotyping concordance in DNA extracted from formalin‐fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Issue 9 (29th July 2015)

5. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Issue 7 (29th April 2016)

7. Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer. (14th December 2020)

8. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. (23rd March 2016)

9. Patient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer. (23rd March 2016)

10. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). (3rd April 2023)